Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

argenx SE American Depositary Shares (ARGX)

https://www.argenx.com

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/18/2017

Market Cap

31,326,085,644

Shares Outstanding

59,190,000

Weighted SO

59,194,488

Total Employees

N/A

Upcoming Earnings

07/25/2024

Similar Tickers

ISEE --.--%

BPMC --.--%

AMLX --.--%

KRTX --.--%

DAWN --.--%

MRTX --.--%

TERN --.--%

APLS --.--%

LEGN --.--%

Beta

0.3130

Last Div

0.0000

Range

327.725-540.49

Chg

-1.0200

Avg Vol

360953

Mkt Cap

31326085644

Exch

NASDAQ

Country

NL

Phone

31 10 703 8441

DCF Diff

19.5813

DCF

400.4810

Div Yield

0.0000

P/S

15.5427

EV Multiple

-99.8542

P/FV

7.3010

Div Yield %

0.0000

P/E

-116.9709

PEG

-3.3441

Payout

0.0000

Current Ratio

8.5339

Quick Ratio

7.8805

Cash Ratio

2.8786

DSO

118.7205

DIO

370.2935

Op Cycle

489.0140

DPO

318.3134

CCC

170.7006

Gross Margin

0.8403

Op Margin

-0.2385

Pretax Margin

-0.1503

Net Margin

-0.1320

Eff Tax Rate

0.1389

ROA

-0.0555

ROE

-0.0716

ROCE

-0.1119

NI/EBT

0.8780

EBT/EBIT

0.6304

EBIT/Rev

-0.2385

Debt Ratio

0.0012

D/E

0.0014

LT Debt/Cap

0.0000

Total Debt/Cap

0.0014

Int Coverage

-228.2790

CF/Debt

-24.8663

Equity Multi

1.1254

Rec Turnover

3.0744

Pay Turnover

1.1467

Inv Turnover

0.9857

FA Turnover

54.5744

Asset Turnover

0.4202

OCF/Share

-2.4502

FCF/Share

-3.5558

Cash/Share

52.2279

OCF/Sales

-0.0722

FCF/OCF

1.4512

CF Coverage

-24.8663

ST Coverage

-24.8663

CapEx Coverage

-2.2162

Div&CapEx Cov

-2.2162

P/BV

7.3010

P/B

7.3010

P/S

15.5427

P/E

-116.9709

P/FCF

-148.3136

P/OCF

-213.8111

P/CF

-213.8111

PEG

-3.3441

P/S

15.5427

EV Multiple

-99.8542

P/FV

7.3010

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Apr 10, 21:47 argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy GlobeNewswire Inc. Jan 06, 06:00 argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Oct 24, 05:00 argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 GlobeNewswire Inc. Jul 16, 04:32 argenx and Zai Lab Announce Approval of Efgartigimod Alfa - GlobeNewswire GlobeNewswire Inc. Jun 17, 05:00 argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024 GlobeNewswire Inc. Jun 04, 05:00 argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference Benzinga Jan 18, 13:28 Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion GlobeNewswire Inc. Jan 18, 01:00 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis GlobeNewswire Inc. Jan 18, 01:00 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis GlobeNewswire Inc. Jan 18, 01:00 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis The Motley Fool Jan 15, 06:30 5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond GlobeNewswire Inc. Jan 08, 01:00 argenx Highlights 2024 Strategic Priorities GlobeNewswire Inc. Jan 08, 01:00 argenx Highlights 2024 Strategic Priorities GlobeNewswire Inc. Jan 08, 01:00 argenx Highlights 2024 Strategic Priorities GlobeNewswire Inc. Jan 02, 01:00 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 02, 01:00 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 02, 01:00 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference Benzinga Dec 21, 14:41 Argenx's Autoimmune Trial Stumble: Analysts Cut Price Targets, Warn of Risky Outcomes Benzinga Dec 21, 14:41 Argenx's Autoimmune Trial Stumble: Analysts Cut Price Targets, Warn of Risky Outcomes Benzinga Dec 21, 07:36 Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday

Revenue Product Segmentation